Heparin coating in biodegradable ureteral stents does not decrease bacterial colonization—assessment in ureteral stricture endourological treatment in animal model

Soria, Federico; Cruz, Julia E. de la; Fernández, Tomás Ramón; Alba, A. Budía; Serrano, Álvaro; Sánchez-Margallo, Francisco M.

doi:10.21037/tau-21-19

Cited by 13 publications

(12 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The optimal combination of polymers and copolymers in the stent is determined by the requirements of their placement in the upper urinary tract [ 10 , 20 ]. The main current limitations to the development of biodegradable ureteral stents (BUS) are related to the control of the degradation rate and the size of the degradation fragments [ 10 , 20 , 21 , 22 , 23 ]. For this reason, a combination of polymers and copolymers with different degradation rates (always with degradation mainly by hydrolysis when placed in urine) are chosen to produce BUS.…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

“…Comparisons of this new design (BraidStent-SF-MMC1 or -2) with other biodegradable ureteral stents made of PGA and Glycomer TM 631 have been experimentally evaluated in the literature [ 21 , 22 , 23 ]. We found that, as with Braidstent groups 1 and 2 in the current study, coating with SF and MMC caused a significant reduction in the rate of ureteral stent degradation, from 6–7 weeks to 13–14 weeks ( Figure 5 ) [ 21 , 22 , 23 ]. Despite significant differences in baseline thickness and weight between the BraidStent-SF, and the BraidStent-SF-MMC1- and -2 groups, no differences in overall degradation time were seen ( Figure 4 , Figure 5 , and Figure 9 ).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of a Coated Mitomycin-Releasing Biodegradable Ureteral Stent as an Adjuvant Therapy in Upper Urothelial Carcinoma: A Comparative In Vitro Study

Soria

Aznar-Cervantes²,

Cruz

et al. 2022

Polymers

Self Cite

View full text Add to dashboard Cite

A major limitation of the treatment of low-grade upper tract urothelial carcinoma is the difficulty of intracavitary instillation of adjuvant therapy. Therefore, the aim of this in vitro study was to develop and to assess a new design of biodegradable ureteral stent coated with a silk fibroin matrix for the controlled release of mitomycin C as a chemotherapeutic drug. For this purpose, we assessed the coating of a biodegradable ureteral stent, BraidStent®, with silk fibroin and subsequently loaded the polymeric matrix with two formulations of mitomycin to evaluate its degradation rate, the concentration of mitomycin released, and changes in the pH and the weight of the stent. Our results confirm that the silk fibroin matrix is able to coat the biodegradable stent and release mitomycin for between 6 and 12 h in the urinary environment. There was a significant delay in the degradation rate of silk fibroin and mitomycin-coated stents compared to bare biodegradable stents, from 6–7 weeks to 13–14 weeks. The present study has shown the feasibility of using mitomycin C-loaded silk fibroin for the coating of biodegradable urinary stents. The addition of mitomycin C to the coating of silk fibroin biodegradable stents could be an attractive approach for intracavitary instillation in the upper urinary tract.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of a Coated Mitomycin-Releasing Biodegradable Ureteral Stent as an Adjuvant Therapy in Upper Urothelial Carcinoma: A Comparative In Vitro Study

Soria

Aznar-Cervantes²,

Cruz

et al. 2022

Polymers

Self Cite

View full text Add to dashboard Cite

show abstract

“…This animal enables the transurethral retrograde insertion of the devices, although antegrade and cystostomy approaches have also been described [24,[29][30][31][32]. The evaluation of the performance in vivo of the urinary devices involves blood and urinalysis, urine culture and imaging tests that include the ultrasonographic assessment of the hydronephrosis degrees [33] (Fig. 2).…”

Section: Porcine Modelmentioning

confidence: 99%

Methodology for the Development and Validation of New Stent Designs: In Vitro and In Vivo Models

et al. 2022

Self Cite

View full text Add to dashboard Cite

The urinary tract is a highly complex, dynamic and variable environment that renders the development of urinary stents extremely challenging. It is mandatory that previous to clinical trials, innovations in urinary medical devices are tested in a preclinical context. The steps of translational research in this regard include in silico, in vitro, ex vivo and in vivo assessments. In this chapter, a critical review of the in vitro stent assessment models is performed, outlining briefly their strengths and weaknesses. Subsequently, a discussion concerning the available animal models for urinary stent evaluation is made with the aim of providing a critical guide for experimental preclinical evaluation of urological devices.

show abstract

“…The stimulus factors of responsive release include pH, enzymes, biological systems, ight, redox, electric, temperature and magnetic [ 22 – 25 ]. Although researchers have done a lot of work in this area, the delivery of antibiotics in a bacterial self-defense and on-demand way is rare [ 26 , 27 ]. Therefore, the use of the microenvironmental characteristics formed after bacterial infection to prepare smart antibacterial coatings that can achieve microenvironmental response to achieve on-demand and precise release of antibacterial drugs at local infection sites is a hot research topic.…”

Section: Introductionmentioning

confidence: 99%

Development of an anti-infective coating on the surface of intraosseous implants responsive to enzymes and bacteria

Liao

et al. 2021

J Nanobiotechnol

View full text Add to dashboard Cite

Background Bacterial proliferation on the endosseous implants surface presents a new threat to the using of the bone implants. Unfortunately, there is no effective constructed antibacterial coating which is bacterial anti-adhesion substrate-independent or have long-term biofilm inhibition functions. Methods Drug release effect was tested in Chymotrypsin (CMS) solution and S. aureus. We used bacterial inhibition rate assays and protein leakage experiment to analyze the in vitro antibacterial effect of (Montmorillonite/Poly-l-lysine-Chlorhexidine)10 [(MMT/PLL-CHX)10] multilayer film. We used the CCK-8 assay to analyze the effect of (MMT/PLL-CHX)10 multilayer films on the growth and proliferation of rat osteoblasts. Rat orthopaedic implant-related infections model was constructed to test the antimicrobial activity effect of (MMT/PLL-CHX)10 multilayer films in vivo. Results In this study, the (MMT/PLL-CHX)10 multilayer films structure were progressively degraded and showed well concentration-dependent degradation characteristics following incubation with Staphylococcus aureus and CMS solution. Bacterial inhibition rate assays and protein leakage experiment showed high levels of bactericidal activity. While the CCK-8 analysis proved that the (MMT/PLL-CHX)10 multilayer films possess perfect biocompatibility. It is somewhat encouraging that in the in vivo antibacterial tests, the K-wires coated with (MMT/PLL-CHX)10 multilayer films showed lower infections incidence and inflammation than the unmodified group, and all parameters are close to SHAM group. Conclusion (MMT/PLL-CHX)10 multilayer films provides a potential therapeutic method for orthopaedic implant-related infections.

show abstract

Heparin coating in biodegradable ureteral stents does not decrease bacterial colonization—assessment in ureteral stricture endourological treatment in animal model

Cited by 13 publications

References 35 publications

Assessment of a Coated Mitomycin-Releasing Biodegradable Ureteral Stent as an Adjuvant Therapy in Upper Urothelial Carcinoma: A Comparative In Vitro Study

Assessment of a Coated Mitomycin-Releasing Biodegradable Ureteral Stent as an Adjuvant Therapy in Upper Urothelial Carcinoma: A Comparative In Vitro Study

Methodology for the Development and Validation of New Stent Designs: In Vitro and In Vivo Models

Development of an anti-infective coating on the surface of intraosseous implants responsive to enzymes and bacteria

Contact Info

Product

Resources

About